CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 21-259

CHEMISTRY REVIEW(S)

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-259 **CHEM. REVIEW #**3 **REVIEW DATE:** 02-MAR-01

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL	31-MAR-00	03-APR-00	12-APR-00
AMENDMENT (BC)	15-DEC-00	18-DEC-00	17-DEC-00
AMENDMENT (BC)	26-DEC-00	03-JAN-01	26-DEC-00
AMEMDMENT (BC)	11-JAN-01	16-JAN-01	16-JAN-01
AMENDMENT (BC)*	13-FEB-01	15-FEB-01	15-FEB-01

* Subject of this review

NAME & ADDRESS OF APPLICANT: Medeva
755 Jefferson Road
P.O. Box 1710
Rochester, NY 14603-1710

DRUG PRODUCT NAME

Proprietary:
Nonproprietary/USAN: Methylphenidate hydrochloride modified release capsules
Code Name/#: none
Chem.Type/Ther.Class: 3S

PHARMACOL. CATEGORY/INDICATION: CNS stimulant

DOSAGE FORM: capsules containing immediate release and extended release beads

STRENGTHS: 20 mg capsules

ROUTE OF ADMINISTRATION: Oral

DISPENSED: _X_ Rx ___ OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA,

$C_{14}H_{19}NO_2 \cdot HCl$



MOLECULAR WEIGHT: 269.77 see ALSO USP 24, page 1088

SUPPORTING DOCUMENTS: DMFs:

DMF Number	Holder Name	Item(s) Reviewed and LOA Date	Review Date(s) and Result
—	Medeva Pharmaceuticals	Methylphenidate Hydrochloride, USP LOA date 3/29/00	CR#6 Adequate 01/31/01

RELATED DOCUMENTS (if applicable): IND 52,318

CONSULTS:

EER: Acceptable dated 01/08/01

OPDRA: 7/27/00 does not recommend the proposed proprietary name of be used because of the potential for confusion with other products. However, final decision regarding the acceptability of this trade name is pending within the ORM Review Division (HFD-120).

REMARKS/COMMENTS:

From a CMC perspective, this NDA may be approved. There are no additional comments to the applicant. NOTE: Now that tests and specifications have been finalized, the applicant agrees to submit an **updated Methods Validation Package**.

Rik Lostritto, Ph.D. Review Chemist

Robert Seevers, Ph.D. Chemistry Team Leader

R/D Init by: _____

filename: C:my files/N21259R3.doc

cc:
Org. NDA 21-259
HFD-120/Division File
HFD-120/R.Lostritto
HFD-120/R.Seevers
HFD-120/A.Homannay

/s/

Richard Lostritto
3/2/01 10:36:56 AM
CHEMIST

Robert H. Seevers
3/2/01 10:45:33 AM
CHEMIST

WITHHOLD 4 PAGE (S)

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-259 **CHEM. REVIEW #**2 **REVIEW DATE:** 31-JAN-01

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL*	31-MAR-00	03-APR-00	12-APR-00
AMENDMENT (BC)	15-DEC-00	18-DEC-00	17-DEC-00
AMENDMENT (BC)	26-DEC-00	03-JAN-01	26-DEC-00
AMEMDMENT (BC)	11-JAN-01	16-JAN-01	16-JAN-01

* Subject of this review

NAME & ADDRESS OF APPLICANT: Medeva
755 Jefferson Road
P.O. Box 1710
Rochester, NY 14603-1710

DRUG PRODUCT NAME

Proprietary:	Metadate MR Capsules
Nonproprietary/USAN:	Methylphenidate hydrochloride modified release capsules
Code Name/#:	none
Chem.Type/Ther.Class:	3S

PHARMACOL. CATEGORY/INDICATION: CNS stimulant

DOSAGE FORM: capsules containing immediate release and extended release beads

STRENGTHS: 20 mg capsules

ROUTE OF ADMINISTRATION: Oral

DISPENSED: _X_ Rx ___ OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA,

$C_{14}H_{19}NO_2 \cdot HCl$



MOLECULAR WEIGHT: 269.77 see ALSO USP 24, page 1088

SUPPORTING DOCUMENTS: DMFs:

DMF Number	Holder Name	Item(s) Reviewed and LOA Date	Review Date(s) and Result
[redacted]	Medeva Pharmaceuticals	Methylphenidate Hydrochloride, USP LOA date 3/29/00	CR#6 Adequate 01/31/01

RELATED DOCUMENTS (if applicable): IND 52,318

CONSULTS:

EER: Acceptable dated 01/08/01

OPDRA: 7/27/00 does not recommend the proposed proprietary name of [redacted] be used because of the potential for confusion with other products. However, final decision regarding the acceptability of this trade name is pending within the ORM Review Division (HFD-120).

REMARKS/COMMENTS:

From a CMC perspective, this NDA is APPROVABLE. There are deficiencies in drug product dissolution testing results and inadequate dissolution specifications noted herein (see DRAFT LETTER COMMENTS).

Rik Lostritto, Ph.D. Review Chemist

Robert Seevers, Ph.D. Chemistry Team Leader

R/D Init by: _____

filename: C:my files/N21259R2.doc

cc:
Org. NDA 21-259
HFD-120/Division File
HFD-120/R.Lostritto
HFD-120/R.Seevers
HFD-120/A.Homannay

/s/

Richard Lostritto
1/31/01 11:46:58 AM
CHEMIST

Robert H. Seevers
1/31/01 11:56:37 AM
CHEMIST

WITHHOLD 10 PAGE (S)

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-259 **CHEM. REVIEW #1** **REVIEW DATE:** 27-DEC-00

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL*	31-MAR-00	03-APR-00	12-APR-00
AMENDMENT (BC)*	15-DEC-00	18-DEC-00	17-DEC-00
AMENDMENT (BC)*	26-DEC-00	pending	26-DEC-00

* Subject of this review

NAME & ADDRESS OF APPLICANT: Medeva
755 Jefferson Road
P.O. Box 1710
Rochester, NY 14603-1710

DRUG PRODUCT NAME

Proprietary:
Nonproprietary/USAN: Methylphenidate hydrochloride modified release capsules
Code Name/#: none
Chem.Type/Ther.Class: 3S

PHARMACOL. CATEGORY/INDICATION: CNS stimulant

DOSAGE FORM: capsules containing immediate release and extended release beads

STRENGTHS: 20 mg capsules

ROUTE OF ADMINISTRATION: Oral

DISPENSED: _X_ Rx ___ OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA,

$C_{14}H_{19}NO_2 \cdot HCl$



MOLECULAR WEIGHT: 269.77 see ALSO USP 24, page 1088

SUPPORTING DOCUMENTS: DMFs:

DMF Number	Holder Name	Item(s) Reviewed and LOA Date	Review Date(s) and Result
[redacted]	Medeva Pharmaceuticals	Methylphenidate Hydrochloride, USP LOA date 3/29/00	CR#4 Inadequate 8/16/00 **CR#5 Inadequate 12/07/00**

RELATED DOCUMENTS (if applicable): IND 52,318

CONSULTS:

EER: Results pending as of the date of this review.

OPDRA: 7/27/00 does not recommend the proposed proprietary name of [redacted] be used because of the potential for confusion with other products. However, final decision regarding the acceptability of this trade name is pending within the ORM Review Division (HFD-120).

REMARKS/COMMENTS:

From a CMC perspective, this NDA is APPROVABLE. There are deficiencies in drug substance and drug product noted herein (see DRAFT LETTER COMMENTS).

Rik Lostritto, Ph.D. Review Chemist

Robert Seevers, Ph.D. Chemistry Team Leader

R/D Init by: _____

filename: C:my files/N21259R1.doc

cc:
Org. NDA 21-259
HFD-120/Division File
HFD-120/R.Lostritto
HFD-120/R.Seevers
HFD-120/A.Homannay

/s/

Richard Lostritto
12/28/00 03:51:18 PM
CHEMIST

Robert H. Seevers
12/28/00 03:55:49 PM
CHEMIST

WITHHOLD 21 PAGE (S)